Skip to content

Personalized functional connectivity guided rTMS treatment for major depressive disorder: an exploratory study

Personalized functional connectivity guided rTMS treatment for major depressive disorder: an exploratory study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054659
Enrollment
Unknown
Registered
2021-12-23
Start date
2022-01-30
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Experimental group1:Intermittent Burst Rapid Pulse Stimulation in Functional Connectivity Localization Group
Experimental group2:Intermittent short bursts of rapid pulse stimulation in the classical coordinate positioning group
Healthy control group:None

Sponsors

The Affiliated Hospital of Hangzhou Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the International Classification of Diseases ICD-10 diagnostic criteria for depression and are diagnosed with mild depression and moderate depressive episodes; 2. Scored by 8<=HAMD<23 (Melzer et al., 2012); Chinese version of Mood Disorder Questionnaire (MDQ)<7; 3. Use the Brief International Neurological Psychiatry Interview 7.0.0 (M.I.N.I.7.0.0) to confirm that the subject is currently suffering from a depressive episode; 4. No gender restriction, aged 20 to 55 years; 5. Subjects who can understand and are willing to strictly abide by the clinical trial protocol to complete the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to magnetic resonance and TMS; 2. Patients who have been judged by the investigator or have been diagnosed with refractory depression (ineffective after 2 or more antidepressants in a sufficient amount and a full course of treatment); 3. Severe heart, liver, kidney disease, no history of thyroid, tumor, blood, rheumatism, malnutrition, nervous system and other diseases; 4. Schizophrenia, bipolar disorder, history of abuse of tobacco, alcohol and other psychoactive substances; 5. People at high risk of suicide; 6. The patient is a pregnant or lactating woman or a person planning to become pregnant; 7. Not taking immunomodulators and hormone preparations for at least half a year, and not taking antipyretic and analgesic drugs within 2 weeks; 8. Those who are deemed inappropriate by the investigators.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;

Secondary

MeasureTime frame
Hamilton Anxiety Scale;Self-rating depression scale;Anxiety self-rating scale;Insomnia Severity Index Scale;Baker Suicidal Ideation Scale;Visual analogue scale;

Countries

China

Contacts

Public ContactZang Yufeng

The Affiliated Hospital of Hangzhou Normal University

zangyf@hznu.edu.cn18606517380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026